Establishment Labs Holdings Inc. (ESTA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Establishment Labs Holdings Inc. is a global medical device company manufacturing and marketing silicone gel-filled breast implants (Motiva Implants) and related aesthetic technologies. The company operates primarily from Costa Rica with subsidiaries in the U.S., Europe, Latin America, and Asia. Following FDA approval in September 2024, the company began commercial sales in the United States in October 2024. The company is currently led by CEO Peter Caldini, who succeeded Juan José Chacón-Quirós in March 2025.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $92,677 |
| Gross Profit | $63,080 |
| Gross Margin | 68.1% |
| Operating Loss | $(31,053) |
| Net Loss | $(37,303) |
| Diluted Net Loss Per Share | $(1.29) |
| Cash and Cash Equivalents (End of Period) | $54,639 |
| Total Debt (Principal) | $221,367 |
| Accumulated Deficit | $(481,995) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14.0% year-over-year (YoY) to $92.7 million, driven primarily by new U.S. sales ($16.3 million in H1 2025 vs. $0.2 million in H1 2024) and growth in EMEA markets.
- Margin Expansion: Gross margin improved to 68.1% from 65.6% in the prior year, attributed to higher selling prices in the U.S. market.
- Operating Expenses: SG&A expenses increased 36.0% YoY to $83.9 million due to personnel costs, shipping, commissions, and marketing associated with U.S. expansion. R&D expenses increased 5.1% to $10.3 million.
- Foreign Currency Impact: The company recorded a significant foreign currency transaction gain of $7.8 million in H1 2025, compared to a loss of $5.8 million in H1 2024, largely due to fluctuations in the Euro and Brazilian Real.
- Cash Position: Cash decreased by $35.7 million during the period, primarily due to operating cash outflows of $39.5 million.
Guidance, Outlook, and Risks
- Outlook: Management expects operating expenses to increase in 2025 due to commercial activities following FDA approval. The company anticipates continued revenue growth in the U.S. and EMEA, though demand in Latin America (specifically Brazil) remains weak. The company does not expect to be profitable in 2025.
- Liquidity: Management believes current cash and operating cash flows are sufficient for at least the next 12 months. A new Inventory Funding Agreement allows for up to $10 million in financing for raw materials.
- Key Risks:
- Regulatory: Ongoing FDA post-approval study (PAS) requirements and potential regulatory changes under the new U.S. administration.
- Supply Chain: Reliance on a single-source supplier (Avantor) for medical-grade silicone.
- Market: Competition from larger entities, potential negative publicity regarding breast implant safety (BIA-ALCL), and macroeconomic pressures on elective procedures.
- Legal: Potential product liability claims and intellectual property litigation.
Investor Verification Checklist
- U.S. Sales Trajectory: Verify the sustainability of the $16.3 million U.S. revenue run rate and the impact of the new Post-Approval Study (PAS) costs ($4-5 million over 10 years).
- Debt Covenants: Confirm compliance with the Oaktree Credit Agreement covenants, specifically the minimum liquidity ($25 million) and gross sales thresholds required to access the remaining Tranche D funding ($25 million).
- Foreign Currency Volatility: Assess the impact of unrealized foreign currency gains on reported net loss and the lack of hedging strategies.
- Inventory Levels: Review the increase in inventory to $94.7 million and the associated obsolescence provisions ($5.5 million) in light of demand fluctuations in Brazil and China.
- Executive Transition: Monitor the integration of the new CEO and the financial impact of the separation and consulting agreements with the former CEO.